XBRANE — Xbrane Biopharma AB Share Price
0.000.00%
Last trade - 00:00- SEK296.26m
- SEK363.65m
- SEK198.72m
- 10
- 25
- 38
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.91 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.42 | ||
| Price to Tang. Book | 7.25 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.49 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -71.57% | ||
| Return on Equity | -139.53% | ||
| Operating Margin | -109.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | 57.62 | 238.73 | 198.72 | 524 | 346.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +7.69 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Directors
- Anders Tullgren NEC (61)
- Martin Amark CEO (39)
- Siavash Bashiri DCE (36)
- Anette Lindqvist CFO (55)
- David Vikstrom CTO (42)
- Erik Domines GCN (57)
- Nina Ivers OTH (51)
- Dina Jurman OTH (39)
- Maria Edebrink MGB (52)
- Xiaoli Hu MGB (39)
- Anders Wallstrom MGB (45)
- Giorgio Chirivi IND (60)
- Ivan Cohen-Tangui IND (60)
- Peter Edman IND (65)
- Eva Nilsagard IND (58)
- Mats Thoren IND (50)
- Karin Wingstrand IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 15th, 2008
- Public Since
- February 3rd, 2016
- No. of Shareholders
- 11,000
- No. of Employees
- 65
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 1,529,483,397
- Address
- Retzius Vag 8, SOLNA, 171 65
- Web
- https://xbrane.com/
- Phone
- +46 855905600
- Auditors
- PricewaterhouseCoopers AB
Upcoming Events for XBRANE
Q1 2025 Xbrane Biopharma AB Earnings Release
Q2 2025 Xbrane Biopharma AB Earnings Release
Q3 2025 Xbrane Biopharma AB Earnings Release
Similar to XBRANE
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Xbrane Biopharma AB share price?
As of Today at 24:09 UTC, shares in Xbrane Biopharma AB are trading at SEK0.19. This share price information is delayed by 15 minutes.
How has the Xbrane Biopharma AB share price performed this year?
Shares in Xbrane Biopharma AB last closed at SEK0.19 and the price had moved by -10.53% over the past 365 days. In terms of relative price strength the Xbrane Biopharma AB share price has underperformed the FTSE Global All Cap Index by -12.77% over the past year.
What are the analyst and broker recommendations for Xbrane Biopharma AB?
The overall consensus recommendation for Xbrane Biopharma AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Xbrane Biopharma AB dividend yield?
Xbrane Biopharma AB does not currently pay a dividend.
Does Xbrane Biopharma AB pay a dividend?
Xbrane Biopharma AB does not currently pay a dividend.
When does Xbrane Biopharma AB next pay dividends?
Xbrane Biopharma AB does not currently pay a dividend.
How do I buy Xbrane Biopharma AB shares?
To buy shares in Xbrane Biopharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Xbrane Biopharma AB?
As of the previous close price of SEK0.19, shares in Xbrane Biopharma AB had a market capitalisation of SEK296.26m.
Where are Xbrane Biopharma AB shares listed?
Here are the trading details for Xbrane Biopharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: XBRANE
What kind of share is Xbrane Biopharma AB?
Based on an overall assessment of its quality, value and momentum Xbrane Biopharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Xbrane Biopharma AB share price forecast for 2025?
The analyst consensus target price for shares in Xbrane Biopharma AB is SEK0.40. That is 106.5% above the last closing price of SEK0.19.
Analysts covering Xbrane Biopharma AB currently have a consensus Earnings Per Share (EPS) forecast of SEK0.07 for the next financial year.
Find out moreWhat is the trend in the Xbrane Biopharma AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xbrane Biopharma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -8.32%.
As of the last closing price of SEK0.19, shares in Xbrane Biopharma AB were trading +6.03% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Xbrane Biopharma AB PE Ratio?
The Xbrane Biopharma AB PE ratio based on its reported earnings over the past 12 months is 2.91. The shares last closed at SEK0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Xbrane Biopharma AB?
Xbrane Biopharma AB's management team is headed by:
- Anders Tullgren - NEC
- Martin Amark - CEO
- Siavash Bashiri - DCE
- Anette Lindqvist - CFO
- David Vikstrom - CTO
- Erik Domines - GCN
- Nina Ivers - OTH
- Dina Jurman - OTH
- Maria Edebrink - MGB
- Xiaoli Hu - MGB
- Anders Wallstrom - MGB
- Giorgio Chirivi - IND
- Ivan Cohen-Tangui - IND
- Peter Edman - IND
- Eva Nilsagard - IND
- Mats Thoren - IND
- Karin Wingstrand - IND